SCHEMBL5146594

SCHEMBL5146594

O=C1NC(=O)C(=C(Cc2ccc(F)cc2)c2ccc(-c3ccc(Cl)c(C(=O)O)c3)o2)N1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.55
KDM4E B2RXH2 8/20 0.55
TTR P02766 1/20 0.44
RPA1 P27694 1/20 0.42
KMT2A Q03164 11/20 0.41
MEN1 O00255 7/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 9/20 0.41
TDP1 Q9NUW8 8/20 0.41
L3MBTL1 Q9Y468 7/20 0.41
CTDSP1 Q9GZU7 4/20 0.41
APEX1 P27695 4/20 0.41
DUSP26 Q9BV47 1/20 0.41
MAPT P10636 8/20 0.41
GAA P10253 2/20 0.41
GALK1 P51570 1/20 0.41
BLM P54132 1/20 0.41
RECQL P46063 5/20 0.40
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147463 0.83 MEN1 (0.44) ALDH1A1KDM4EKMT2AMEN1POLB
SCHEMBL5147466 0.83 MEN1 (0.44) ALDH1A1KDM4EKMT2AMEN1POLB
SCHEMBL5145191 0.80 RPA1 (0.44) ALDH1A1KDM4ETTRRPA1KMT2A
SCHEMBL5144980 0.75 TTR (0.46) ALDH1A1KDM4ETTRRPA1KMT2A
SCHEMBL5144975 0.75 TTR (0.46) ALDH1A1KDM4ETTRRPA1KMT2A
SCHEMBL6721173 0.71 KDM4E (1.00) ALDH1A1KDM4EKMT2AMEN1NPC1
SCHEMBL5145012 0.70 MEN1 (0.42) ALDH1A1KDM4EKMT2AMEN1POLB
SCHEMBL5164488 0.70 KMT2A (0.71) ALDH1A1KDM4ETTRKMT2AMEN1
SCHEMBL6393879 0.69 TDP1 (0.74) ALDH1A1KDM4ETTRKMT2AMEN1
SCHEMBL5146587 0.69 TDP1 (0.74) ALDH1A1KDM4ETTRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 ALDH1A1 2413/4885KDM4E 4569/4885TTR 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.